Actelion Ltd.
is a leading
biopharmaceutical
company focused
on the discovery,
development
and commercialization
of innovative drugs
for diseases
with significant
unmet medical needs.

Actelion delivers strong nine months results

Jean-Paul Clozel, CEO “Actelion continues to make
significant progress. We are launching Opsumit
successfully around the globe and we are
very close to filing selexipag with
healthcare authorities in the EU and the US.”

Jean-Paul Clozel, CEO “Actelion continues to make
significant progress. We are launching Opsumit
successfully around the globe and we are
very close to filing selexipag with
healthcare authorities in the EU and the US.”

Global Actelion

Hotspot of possibilities

Actelion has subsidaries in over 30 countries, covering all major pharmaceutical markets worldwide

Hotspot of possibilities

Actelion has subsidaries in over 30 countries, covering all major pharmaceutical markets worldwide

Shareprice

ATLN SIX Swiss Exchange

Shareprice
At 17:30:20 CET 22/10/2014
CHF 108,70Up Down image
+3,20 (+3,03%)